Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Mixed salts of a single-entity amphetamine (ADDERALL XR), ADDERALL XR
Mixed salts of a single-entity amphetamine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Adderall XR (10 mg) | EXPERIMENTAL | - |
| Adderall XR (20 mg) | EXPERIMENTAL | - |
| Adderall XR (30 mg) | EXPERIMENTAL | - |
| Adderall XR (40 mg) | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Mixed salts of a single-entity amphetamine | DRUG | - |
| Atomoxetine hydrochloride | DRUG | - |
| Mixed salts of a single-entity amphetamine (ADDERALL XR) | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * primary diagnosis of ADHD * not naive to pharmacologic ADHD treatment * valid driver's license with a minimum of 3 years driving experience Exclusion Criteria: * recent history of drug dependence or substance use disorder * any specific cardiac condition that would, in the o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
| Axsome Therapeutics, Inc. | AXSM | 3 | PHASE3 | Solriamfetol |
ADDERALL XR is used to treat Attention Deficit Hyperactivity Disorder (ADHD), including Attention Deficit Disorder With Hyperactivity. It is a small molecule treatment studied in adolescents aged 13 to 17 and in adults with ADHD. It is developed by Takeda Pharmaceutical Company Limited.
ADDERALL XR is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the company associated with the clinical development program for this mixed salts of a single-entity amphetamine product in ADHD.
ADDERALL XR has been studied in Phase 3 clinical development for ADHD. Its trials are listed as completed, and no active trials are currently recorded. The program includes a completed Phase 3 study in adolescents aged 13 to 17 and a completed Phase 3 simulated driving study in adults.
ADDERALL XR has been evaluated in completed Phase 3 trials, including NCT00507065, which studied safety and efficacy in adolescents aged 13 to 17 with ADHD and enrolled 329 participants, and NCT00557960, which compared ADDERALL XR and atomoxetine to placebo on simulated driving safety and cognitive functioning in adults with ADHD.
Yes, ADDERALL XR is the brand name for mixed salts of a single-entity amphetamine. The two names refer to the same product, so searches for either term describe the same ADHD treatment developed by Takeda Pharmaceutical Company Limited.
ADDERALL XR trials were randomized, double-blind, and placebo-controlled. The adolescent Phase 3 study NCT00507065 enrolled 329 participants aged 13 and older with ADHD, while NCT00557960 enrolled 36 adults and assessed simulated driving safety, performance, and cognitive functioning.